Urban economics

EQS-News: Steinhoff International Holdings N.V. : LAUNCH OF PLACING OF UP TO 240 MILLION SHARES IN PEPKOR HOLDINGS LIMITED

Retrieved on: 
Monday, February 13, 2023
Urban economics, United Kingdom, Person, Steinhoff, African, Sale, Finance, Management, JSE, European Union (Withdrawal) Act 2018, European Economic Area, Prospectus, Security (finance), Financial adviser, Property management, EU

The distribution of this Announcement and the offering for sale of the Placing Shares in certain jurisdictions may be restricted by law.

Key Points: 
  • The distribution of this Announcement and the offering for sale of the Placing Shares in certain jurisdictions may be restricted by law.
  • There will be no public offer of the Placing Shares in the United States of America or in any other jurisdiction.
  • Any investment decision to acquire Placing Shares pursuant to the Placing must be made solely on the basis of publicly available information.
  • The Placing Shares to be sold pursuant to the Placing are not admitted to trading on any stock exchange other than the JSE.

EQS-News: Steinhoff International Holdings N.V. : RESULTS OF THE PLACING OF 265 MILLION SHARES IN PEPKOR HOLDINGS LIMITED

Retrieved on: 
Sunday, February 12, 2023
Urban economics, United Kingdom, Person, Steinhoff, African, Sale, Finance, Management, JSE, European Union (Withdrawal) Act 2018, European Economic Area, Prospectus, Security (finance), Financial adviser, Property management, EU

The distribution of this Announcement and the offering for sale of the Placing Shares in certain jurisdictions may be restricted by law.

Key Points: 
  • The distribution of this Announcement and the offering for sale of the Placing Shares in certain jurisdictions may be restricted by law.
  • There will be no public offer of the Placing Shares in the United States of America or in any other jurisdiction.
  • Any investment decision to acquire Placing Shares pursuant to the Placing must be made solely on the basis of publicly available information.
  • The Placing Shares to be sold pursuant to the Placing are not admitted to trading on any stock exchange other than the JSE.

Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair® (Omalizumab)

Retrieved on: 
Monday, February 6, 2023
Advanz Pharma, Urban economics, European Economic Area, Omalizumab, Respiratory disease, Patient, Fine chemical, Generic drug, IQVIA

Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair® (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand

Key Points: 
  • Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair® (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand
    REYKJAVIK, Iceland, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has entered into an exclusive agreement with Advanz Pharma, for the commercialization of AVT23, a proposed biosimilar to Xolair® (omalizumab).
  • The agreement covers the European Economic Area, UK, Switzerland, Canada, Australia and New Zealand.
  • “We look forward to working with Advanz Pharma on the commercialization of this important therapy in respiratory disease,” said Anil Okay, Chief Commercial Officer of Alvotech.
  • “This agreement highlights our joint commitment to provide better patient access to more affordable biologics around the world.”
    According to the agreement, Alvotech will be responsible for development and manufacture, while Advanz Pharma will handle registration and commercialization.

MDxHealth Announces Pricing of Offering of ADSs in the United States

Retrieved on: 
Friday, February 3, 2023
Finance, United Kingdom, Urban economics, European Economic Area, Central bank, Offering, ADS, Article 49 of the French Constitution, European Central Bank, Sale, Article 19, Financial services, Article, Person, Order, Prospectus, Financial Services and Markets Act 2000, EUR, Security (finance), EU

This press release contains forward-looking statements regarding the expected closing of the Offering and the intended use of proceeds from the Offering.

Key Points: 
  • This press release contains forward-looking statements regarding the expected closing of the Offering and the intended use of proceeds from the Offering.
  • The Offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed.
  • This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of mdxhealth in any jurisdiction.
  • No public offering will be made and no one has taken any action that would, or is intended to, permit a public offering in any country or jurisdiction, other than the United States, where any such action is required, including in Belgium.

MDxHealth Announces Launch of Offering of ADSs in the United States

Retrieved on: 
Wednesday, February 1, 2023
Finance, United Kingdom, Urban economics, European Economic Area, Offering, Article 49 of the French Constitution, Sale, Article 19, Financial services, Article, Person, Order, Prospectus, Financial Services and Markets Act 2000, Security (finance), EU

This press release contains forward-looking statements regarding the proposed offering and the intended use of proceeds from the offering.

Key Points: 
  • This press release contains forward-looking statements regarding the proposed offering and the intended use of proceeds from the offering.
  • The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
  • This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of mdxhealth in any jurisdiction.
  • No public offering will be made and no one has taken any action that would, or is intended to, permit a public offering in any country or jurisdiction, other than the United States, where any such action is required, including in Belgium.

EBA updates list of CET1 instruments

Retrieved on: 
Monday, January 16, 2023
Commission, Competent authority, CRR, Article, Review, Capital Requirements Regulation 2013, EBA, Authority, Urban economics, Joint committee, Common equity, EEA, Union, European Banking Authority, European Economic Area, Article 29 Data Protection Working Party, European, Security (finance), EU

Since the publication of the last updated list of CET1 capital instruments on 8 December 2021, the EBA has continued monitoring and assessing the capital instruments issued by EU institutions and their eligibility towards the criteria set in the CRR.

Key Points: 
  • Since the publication of the last updated list of CET1 capital instruments on 8 December 2021, the EBA has continued monitoring and assessing the capital instruments issued by EU institutions and their eligibility towards the criteria set in the CRR.
  • Following the Joint Committee EEA Decision adopting the CRR1 that entered into force on 1 January 2020, the EBA assessed all types of CET1 instruments issued in the EEA counties in order to add them to the CET1 list.
  • Given that all instruments were considered as fully compliant with the eligibility criteria set out in the CRR, the instruments are now included in the updated CET1 list and new highlighted rows have been added to flag these instruments.
  • In particular, the CRR2 provides for the EBA to be consulted ex ante for new forms of instruments that are not yet included in the CET1 list in order for them to be classified as CET1 instruments.

EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Listing of 2,054,796 Shares

Retrieved on: 
Sunday, November 27, 2022
Inflammation, Euroclear, Financial Services and Markets Act 2000, Therapy, European Economic Area, Protein, Drug development, Security (finance), Communication, AFRICA, Kohlberg Kravis Roberts, Qualifying investor alternative investment fund, Patient, Financial services, Prospectus, Risk, Fibrosis, Person, Relevance (Person of Interest), Issuer, KKR, European Union (Withdrawal) Act 2018, Disease, EUR, AMERICA, Urban economics, Council, Sale, Cancer, Article, European Parliament, Euronext Amsterdam, Investment, Pharmaceutical industry, EU

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA.

Key Points: 
  • NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA.
  • Vivoryon is pioneering a unique therapeutic approach to overcoming the challenges in Alzheimers disease ("AD") drug development.
  • Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines.
  • Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases.

EDPB adopts Recommendations on the application for approval and on the elements and principles to be found in Controller Binding Corporate Rules

Retrieved on: 
Friday, November 25, 2022
Urban economics, BCR, Element, Max Schrems, European Economic Area, GDPR, Medical device

During its November plenary, the EDPB adopted Recommendations on the application for approval and on the elements and principles to be found in Controller Binding Corporate Rules (BCR-C).

Key Points: 
  • During its November plenary, the EDPB adopted Recommendations on the application for approval and on the elements and principles to be found in Controller Binding Corporate Rules (BCR-C).
  • These recommendations form an update of the existing BCR-C referential, which contain criteria for BCR-C approval, and merge it with the standard application form for BCR-C.
  • The new recommendations build upon the agreements reached by data protection authorities in the course of approval procedures on concrete BCR applications since the entering into application of the GDPR.
  • The recommendations provide additional guidance and aim to ensure a level playing field for all BCR applicants.

EQS-News: tonies SE: tonies to launch cash capital increase targeting gross proceeds of up to EUR 60 million

Retrieved on: 
Friday, November 11, 2022
Forward-looking statement, Finance, Nature, Urban economics, Financial services, European, Council, Person, European Parliament, Securities Act of 1933, United Kingdom, Failure, II, European Economic Area, Achievement, Financial Services and Markets Act 2000, Terminology, SE, News, Acquisition, Directive 2014/65/EU, Relevance (Person of Interest), Security (finance), Medical device, EU

These forward-looking statements are based upon current expectations and assumptions regarding anticipated developments and other factors affecting the tonies SE.

Key Points: 
  • These forward-looking statements are based upon current expectations and assumptions regarding anticipated developments and other factors affecting the tonies SE.
  • These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described in this document.
  • Neither tonies SE nor any other person accepts any responsibility for the accuracy of the opinions expressed in this document or the underlying assumptions.
  • This release may contain forward looking statements, estimates, opinions and projections with respect to anticipated future performance of tonies SE (forward-looking statements).

EQS-News: Eleving Group S.A.: Eleving Group reports unaudited results for nine months ended on 30 September 2022

Retrieved on: 
Monday, November 7, 2022
Zero, Urban economics, Communication, Prospectus, CO2, ICR, Growth, ESG, Financial services, Sale, EUR, Eurobond, Parental leave, Relevance (Person of Interest), European Economic Area, United Kingdom, Uncertainty, EBITDA, Finance, Securities Act of 1933, KID, Financial Services and Markets Act 2000, Natural borrowing limit, FX, Environment, The Elevation Group, KES, NPL, Policy, Person, News, Financial Times, Mission Zero, Security (finance), Renewable energy, Bank, Real estate, Film, Airline, Baltic states, Q3, Group

Tightened underwriting policy has been introduced throughout the Group due to the economic uncertainty surrounding the operating jurisdictions.

Key Points: 
  • Tightened underwriting policy has been introduced throughout the Group due to the economic uncertainty surrounding the operating jurisdictions.
  • Additionally, the Group has implemented a support program for employees with kids and a re-onboarding plan for employees returning from parental leave.
  • The Group has continued to diversify its capital structure by raising EUR 4 mln debt via private bond issuance in Kenya.
  • It has been another excellent quarter for Eleving Group since the business continues to grow steadily as evidenced by all the fundamental figures.